SCOPE NOTE:
Bioprocessing includes cell culture, protein expression, protein
production, protein purification, contract manufacturing, CMC Chemistry
manufacturing and controls,
upstream and downstream processing, analytical development and quality,
formulation and stability, cell and gene therapy production, and
manufacturing.
Related glossaries include Biologics
Cell & tissue technologies
Drug delivery & formulation Protein technologies
Bioprocessing Summit Europe
March 24-26, 2020
Lisboa Portugal
Program | Upstream
processing, Downstream processing, Cell and Gene therapy CMC and
Manufacturing
Advances in Recovery and Purification
March 19-21, 2019
Lisboa, Portugal
Program |
As product pipelines diversify from traditional mAbs, downstream
processing teams are under increasing pressure to develop new recovery
and purification platforms, while at the same time, continue to reduce
timelines, costs and minimize bottlenecks for traditional mAbs
therapies.
Bioproduction: Scale, Bioreactors and Disposables
March 19-21, 2019
Lisboa, Portugal
Program |
reviews
the finesse required to manufacture biologics including scale-down
models, scaling up production, engineering bioreactors, single-use
systems, and ensuring quality, within the context of increasing
productivity, while ensuring safety and achieving reduced costs. A
holistic review of bioprocessing will be explored, as well as practical
details, such as monitoring and analyzing processes, and examining in
detail how bioreactors process cells and how to keep those cells happy.
Continuous Processing for Biopharmaceuticals
March
19-20, 2019 Lisboa, Portugal
Program |
Continuous processing has proven to reduce manufacturing costs and
increase efficiencies, but what are the practical considerations when
implementing this technology at scale? Which technology gaps still
remain, how can companies ensure process control and stability, and
where should companies be focusing resources and investments to ensure
clinical and commercial success?
Optimising Cell Culture Technology
March 19-20, 2019
Lisboa, Portugal
Program |
The ubiquitous task of culturing cells is recognised as an established
technology; yet, meeting the demands of industry pushes the need to
increase titre, and decrease the time and resources necessary to meet
project goals. CRISPR, modeling and computational insights will be
discussed in the continuing efforts to improve yield.
analytical development:
Accelerating Analytical Development Optimizing the Speed and Efficiency
of Key Analytical Steps in Biotherapeutic Development August 12-16, 2019
BOSTON MA Research
for this meeting revealed that industry analytical groups are facing
increased pressure to deliver key analytical studies used in candidate
selection, process development, clinical development and regulatory
submissions faster than ever before – and at lower costs. Accelerating
Analytical Development offers a best practices forum in which
industry scientists and managers can exchange ideas on strategies, new
technologies and the integration of analytical methods in support of
these goals. The conference will address the most important roles of the
analytical function at every stage of development and provide insights
on how different organizations are addressing these challenges
http://www.bioprocessingsummit.com/Preclinical-Analytical-Development/
baculoviridae:
Family of INSECT VIRUSES containing two subfamilies:
Eubaculovirinae (occluded baculoviruses) and Nudibaculovirinae (nonoccluded
baculoviruses). The Eubaculovirinae, which contain polyhedron-shaped
inclusion bodies, have two genera: NUCLEOPOLYHEDROVIRUS and
GRANULOVIRUS. Baculovirus vectors are
used for expression of foreign genes in insects. MeSH 1991
biomanufacturing: For the
remainder of this paper, we will define “biomanufacturing “ as
“Use of living genetically modified organisms or living genetically
modified cells to manufacture a product.” A genetically modified
organism is defined as “an organism whose genetic characteristics have
been altered by the insertion of a modified gene or a gene from another
organism or by modification/disabling/deletion of a gene, using the
techniques of genetic engineering.” A variety of living genetically
modified organisms, such as bacteria, fungi, algae, plants and animals
could be used for biomanufacturing. This broad definition of
biomanufacturing includes in scope projects that address critical
processes in the manufacture of biopharmaceuticals (health related) as
well as nonbiopharmaceutical (non-health related) products. NIST, MANUFACTURING:
Manufacturing and Biomanufacturing: Material Advances and Critical
Processes 2011 DRAFT
http://www.nist.gov/tip/wp/upload/manufacturing_biomanufacturing_wp_08_11.pdf
Biomanufacturing
is defined here as the production of large molecules that cannot be
directly synthesized or extracted. Relatively small, simple proteins are
produced by microbial fermentation (e.g., insulin and human growth
hormone in E. coli,
recombinant hepatitis B vaccine in yeast). Larger, more complex
proteins such as EPO, tPA,
and monoclonal antibodies require the addition of specific sugar side
chains to the protein backbone (a process termed glycosylation). Only
mammalian cells — Chinese hamster ovary cell lines are the
predominant industry standard — can naturally attach the right
sequence of sugar molecules and fold the protein into its correct shape
for it to be functionally active. Technology
Roadmaps The Canadian Biopharmaceutical Industry Technology Roadmap —
Biomanufacturing, Industry Canada 2010 http://www.ic.gc.ca/eic/site/trm-crt.nsf/eng/rm00379.html
bioprocess: Bioprocesses
use living cells and their components to develop innovative products.
The Sector develops microbial, enzymatic and advanced cell-based
processes from inception to industrial scale. These processes can then
be used by industrial partners for the production of valued compounds
such as bio-therapeutics, enzymes, green products and other biological
products. BRI's unique bioprocess facility is equipped for the
production of large amounts of drug target protein, in a biologically
active form, for further studies along the drug development process.
BRI's scientists and engineers also develop unique expression vectors,
and use both fed-batch and perfusion strategies in the growth and
production of recombinant proteins in bacteria, yeast, insect, and
mammalian cells. For a specific protein, the Bioprocess research team
can develop a novel, integrated recombinant production process and scale
it up, through iterative processing, to optimize the yield and
biological activity of the product. Bioprocess Sector, National Research
Council Canada 2009
http://www.nrc-cnrc.gc.ca/eng/programs/bri/bioprocess-sector.html
http://en.wikipedia.org/wiki/Bioprocess http://en.wiktionary.org/wiki/bioprocessing
Bioprocess Data Management
January 20-21, 2020 • San Diego, CA The biopharmaceutical industry is
meeting increasing demands and costs for biotherapeutics through process
optimization. Advanced instrumentation with sampling techniques, new
sensor technologies and analyzers have emerged to monitor both upstream
and downstream processes.
When well-prepared and analyzed, this
data leads to process knowledge, process control, and continuous
improvement resulting in greater speed, quality, and economy … addresses
statistical analysis strategies including multivariate data analysis
(MVDA), quality by design (QbD), process analytical technology (PAT),
and multi-attribute method (MAM), allowing for optimized and informed
control of bioprocessing.
bioprocess engineering: http://en.wikipedia.org/wiki/Bioprocess_Engineering
bioprocessing: The
Bioprocessing Summit August
12-16, 2019 • Boston,
MA upstream and downstream
processing, analytical development and quality, formulation and
stability, cell and gene therapy production and manufacturing.
Bioproduction: Scale, Bioreactors & Disposables Making It Work August
14-15, 2019 BOSTON MA
reviews the finesse required to manufacture biologics including
scale-down models, scaling up production, engineering bioreactors,
single-use systems, and ensuring quality within the context of
increasing productivity; while ensuring safety and achieving reduced
costs. A holistic review of bioprocessing will be explored, as well as
practical details, such as monitoring and analyzing processes, and
examining in detail how bioreactors process cells and how to keep those
cells happy. The conference will address robust production processes
and next-generation technologies, while improving manufacturing
platforms and ensuring product quality..
http://www.bioprocessingsummit.com/Bioproduction/
bioreactors: Tools
or devices for generating products using the synthetic or chemical
conversion capacity of a biological system. They can be classical
fermentors, cell culture perfusion systems, or enzyme bioreactors. For
production of proteins or enzymes, recombinant microorganisms such as
bacteria, mammalian cells, or insect or plant cells are usually chosen.
MeSH 1997 Narrower
terms: microreactors, microbioreactors
biosimilars: Regulatory
Biotherapeutics Analytical Summit
June 1-5, 2020• Alexandria VA
Program |
Method Development, Qualification & Validation, Advances in
Characterization Methods & Approaches and Comparability & Biosimilarity
biotransformation: Conversion
of a chemical from one form to another by a biological organism. NLM
Toxicology Tutor, Glossary http://sis.nlm.nih.gov/enviro/toxtutor/Tox1/glossb.htm
The
process whereby a substance is changed from one chemical to another (transformed) by
a chemical reaction within the body. Metabolism or metabolic
transformations are
terms frequently used for the biotransformation process.
However, metabolism is sometimes not specific for the transformation
process but may include other phases of toxicokinetics. National
Library of Medicine, Toxicology Tutor former definition for
biotransformation
cell
culture:
Optimizing Cell Culture Technology
Enhancing Knowledge for Growing Cells
August 12-13, 2019 Boston,
MA
Program |
By focusing solely on culturing cells, “Optimizing Cell Culture
Technology” has long become the established ‘must attend’ international
conference for keeping up with emerging trends and technologies that
lead to improved qualities and higher titers. The conference examines
breakthrough strategies and technologies for improving cell cultivation,
including genome engineering and next-gen analyses and techniques, such
as developing cell culture models. Industry experts provide insights
into optimizing conditions as well as cell biology in the effort to
improve yield, while also addressing the future of cell culture in an
expanding market where demand continues to increase.
The in vitro propagation of animal of plant cells, in an artificial
nutrient medium. IUPAC Biotech
cell culture techniques: A
technique for maintaining or growing CELLS in vitro. Cultures of
dispersed cells derived directly from fresh TISSUES are called primary
cell cultures. Cultures may also derive from established CELL LINE
usually stored frozen. MeSH 2005 (1996) Narrower
terms: CHO cells, cell line; hybridomas, mammalian cell culture,
stem cells
cell
line: Defined unique population of cells
obtained by culture from a primary implant through numerous generations.
IUPAC Tox Often mammalian. Narrower
terms: CHO cells, cell strain; Broader term: cell culture
ATCC American Type Culture Collection http://www.atcc.org/
cell line development:
Optimizing Cell Line Development Enhancing Expression August 15-16, 2019
Boston MA
Cell
Line Development has reached a new plateau influenced by genomic
research and insights, along with emerging technologies that are pushing
cell engineering into an uncharted future. The “Optimizing Cell Line
Development” conference brings together cell line development experts
who are forging this new era. They will share how to best optimize
codons, construct vectors, and how to select and engineer clones and
host systems, while maintaining stability and consistency. The
conference will also focus on genomic research for CHO and other
systems, as well as glycoengineering, systems biology, assays, and
pathway delineation. In addition, challenges for introducing new
technologies will be discussed, along with an overview of industrial
trends and regulatory perspectives.
http://www.bioprocessingsummit.com/Cell-Line-Development/
cell
strain: Cells
having specific properties or markers derived from a primary culture or cell
line. IUPAC Toxicology
Cell
Therapy CMC and Analytics August 12-13, 2019 BOSTON MA
To ensure the quality, safety and rapid production of cell therapies,
companies must keep on top of their CMC and analytical strategies.
However, cell-based therapies are extremely complex to analysis with
high variability. Cambridge Healthtech Institute’s Cell Therapy CMC and
Analytics meeting focuses on the technical and regulatory requirements
needed to advance the analysis, quality and development of cell
therapies with in-depth case studies and regulatory feedback on CMC
development, product release, assay development and validation, flow
cytometry, target product profiles, critical quality attributes,
critical process parameters, and product release.
http://www.bioprocessingsummit.com/Cell-Therapy-CMC/
See also CMC
Chemistry
Cell
Therapy Manufacturing Commercializing Cell-Based Therapies August 14-15,
2019 BOSTON MA
The recent approvals of CAR T therapies
Yescarta and Kymiriah represent a major breakthrough for the cell
therapy industry. But how will we manufacture these products at scale?
And what platforms, technologies and cell processes can we expect to see
in the future? Do the answers lie in traditional biomanufacturing
methods or custom-made processes?
CHI’s Cell Therapy Manufacturing
meeting takes an in-depth look at the practical challenges of
manufacturing autologous and allogenic cell therapies at scale, with
dedicated sessions on cell processing, scalability, bioreactors,
next-generation production technologies, automation, closed systems,
supply chain and facility design. The meeting will feature extensive
sessions on CAR-Ts, NK cells, TCRs and manufacturing CRISPR-based CAR Ts
at scale.
http://www.bioprocessingsummit.com/Cell-Therapy-Bioproduction/
cGMP
current Good Manufacturing Practice: Facts
about https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps
See also GMP Good Manufacturing Practice
characterization methods: Advances in
Characterization Methods & Approaches
From proteins and antibodies to cell and
gene therapies
June 2-3, 2020 Alexandria VA
As new biotherapeutic formats progress through development into the
regulatory process, analytical characterization needs to be even more
robust, adaptable and creative. These new modalities present challenges
to analytical scientists in product and process development, CMC as well
as regulatory agencies.
https://www.biotherapeuticsanalyticalsummit.com/characterization
Characterization of Biotherapeutics Exploring the Analytical Challenges
of Today’s Complex Biologics
APRIL 8-9, 2019 BOSTON MA As
new product formats progress through development and into the regulatory
process, the role of analytical characterization is taking on new
meaning. Very new modalities present challenges to both analytical
scientists and regulatory agencies alike, and this steep learning curve
requires a near-constant cycle of adaptation and innovation.
The agencies are requiring sponsors to provide ever more complex
data across a wide range of analytical methods, and instrumentation
suppliers are striving to support this new era with unique product
features, software and feature combinations.
https://www.pegsummit.com/Biotherapeutics-Characterization/
CHO
cells Chinese Hamster Ovaries: Chinese
hamster ovary (CHO) cells are the predominant cell factory for the
production of biotherapeutics.
January
16-17, 2019 • San Diego, CA | CHO
cells’ rapid rise in production prominence is due to their adaptability
to various culture conditions, gene plasticity, and ability in proper
folding, posttranslational modifications, and glycosylation of desired
proteins. Thus, advances in CHO cell lines and culture continue to
significantly improve biotherapeutic production. This achievement is due
to progress in engineering stable and transient cell lines, enhancing
cell culture conditions and performance, as well as optimizing process
development. When all are accomplished, higher-production titers and
better product quality result.http://www.chi-peptalk.com/cho-cells/
Broader term: mammalian cell culture
Comparability &
Biosimilarity June
4-5, 2020 • Alexandria VA | explores
the dynamic advances in analytical technologies, from novel approaches
such as machine learning and data analytics, to cutting-edge
technologies such as MS, MAM, NMR for characterization, as well as best
practices for comparability and analytical similarity assessments, with
the goal of determining a product's robustness, stability, safety, and
consistency.
https://www.biotherapeuticsanalyticalsummit.com/Comparability/
Continuous Processing in Biopharm Manufacturing Enabling Technologies &
Creative Approaches August 12-13, 2019 BOSTON MA
Whether you have implemented it, or are considering it in one way or
another, continuous processing has become a household word among
biopharma companies. Continuous manufacturing has the potential to
increase the efficiency, flexibility, agility and robustness of
manufacturing by reducing the number of steps and holds, utilizing
smaller equipment and facilities, improving product quality and enabling
real-time release.
http://www.bioprocessingsummit.com/continuous-processing/
contract manufacturing: Production of goods by one
firm, under the label or brand of another firm. Contract manufacturers
provide such service to several (even competing) firms based on their
own or the customers' designs, formulas, and/or specifications. Also
called private label manufacturing. Business Dictionary
http://www.businessdictionary.com/definition/contract-manufacturing.html
cultured cells: Cells
propagated in vitro in special media conducive to their growth. Cultured
cells are used to study developmental, morphologic, metabolic,
physiologic, and genetic processes, among others MeSH 1972
Digital BioManufacturing August 14-15 ,
2019 BOSTON MA
Industry 4.0, internet of things, big data, AI … these are words that we
are seeing and hearing around us, enabling exciting developments such as
autonomous cars, smart factories and connected cities. This wave of
transformation is coming to the biopharm industry, promising to
revolutionize the way we approach biologics development to
manufacturing. http://www.bioprocessingsummit.com/manufacturing-efficiencies/
disposables: See
Bioproduction scale bioreactors & disposables
display of antibodies
Display of Antibodies
2019 April 8-9 Boston MA
showcases innovation in discovery, design and engineering of biologics
through molecular evolution using phage, yeast and other display
methodologies. The proliferation of novel constructs is possible through
methods to improve library design, pharmacological and biophysical
properties to create drug molecules with greater potency, modes of action,
target specificity and activity than previously achievable.
Related terms:
phage display, yeast display
downstream processing:
The downstream part of a bioprocess refers to the part where the cell
mass from the upstream are processed to meet purity and quality
requirements. Downstream processing is usually divided into three main
sections: cell disruption, a purification section and a polishing
section. Wikipedia bioprocessing accessed 2018 Aug 17
https://en.wikipedia.org/wiki/Bioprocess
See related upstream processing
dynamic light scattering:
a technique in physics that
can be used to determine the size distribution profile of small particles in suspension or polymers in solution.[1] In
the scope of DLS, temporal fluctuations are usually analyzed by means of
the intensity or photon auto-correlation function (also known as photon
correlation spectroscopy or quasi-elastic
light scattering).
In the time domain analysis, the autocorrelation function (ACF) usually
decays starting from zero delay time, and faster dynamics due to smaller
particles lead to faster decorrelation of scattered intensity trace. It
has been shown that the intensity ACF is the Fourier transformation of
the power
spectrum,
and therefore the DLS measurements can be equally well performed in the
spectral domain.[2][3] DLS
can also be used to probe the behavior of complex fluids such as
concentrated polymer solutions. Wikipedia
https://en.wikipedia.org/wiki/Dynamic_light_scattering
expression vector: An expression
vector, otherwise known as an expression construct, is
usually a plasmid or
virus designed for gene
expression in cells. The vector is
used to introduce a specific gene into
a target cell, and can commandeer the cell's mechanism for protein
synthesis to produce the protein encoded by
the gene. Expression vectors are the basic tools in biotechnology for
the production
of proteins.
Wikipedia accessed 2018 Aug 22
https://en.wikipedia.org/wiki/Expression_vector
fluidic
system: Device
for synthesis or screening in which fluids such as reagents or assay buffers
may be directed to specified locations by the opening and closing of
valves in a stationary network of tubes and wells. Related term:
robotic systems; Narrower term microfluidics
freeze
drying See lyophilization
GAMP
Good Automated Manufacturing Process: Wikipedia
http://en.wikipedia.org/wiki/Good_Automated_Manufacturing_Practice
Gene Therapy CMC and Manufacturing
20-21 MARCH 2019
Lisbon Portugal
Lisboa
Program
The vector-based gene therapy industry
has undergone rapid advances over the last twelve months and shows no
sign of slowing down. The clinical results are beyond encouraging.
However, the pressure is now on CMC, analytical, process development and
manufacturing department to produce these therapies at scale.
The Gene Therapy CMC and Bioproduction conference examines the practical
challenges facing the production, characterization and quality control
of vector-based gene therapies, with dedicated sessions on AAV and
lentivirus-based platforms as well as oncolytic viruses, CRISPR and
other gene editing therapies. Topics include new and emerging analytical
strategies, upcoming regulations and the latest manufacturing strategies
for large- and small-scale production.
See also CMC
Chemistry
Gene therapy Bioprocessing Summit stream
2019 August 14-16
The Gene Therapy CMC and Manufacturing stream features two back-to-back
conferences focusing on the critical challenges facing the analysis,
characterization, quality control and manufacture of viral vector-based
gene therapies. Examples come from both AAV and lentivirus-based
therapies. Topics include impurity analysis, potency assay development,
process development, scale-up, clinical and commercial manufacturing,
purification and formulation.
http://www.bioprocessingsummit.com/stream/gene-therapy/
Gene
Therapy CMC and Analytics August 14-15, 2019 BOSTON MA
Gene
therapy is an extremely promising technique for the treatment of
incurable diseases such as cancer and genetic disorders such as
hemophilia. However, the analysis, characterization and delivery of
these unique products remain an issue. Cambridge Healthtech Institute’s Gene Therapy CMC and Analytics meeting uncovers the practical
challenges facing vector-based gene therapy analytics, assay
development, quality control, vector development and delivery.
http://www.bioprocessingsummit.com/gene-therapy-cmc/
Gene
Therapy Manufacturing August 15-16, 2019 BOSTON MA
It
is an exciting time for gene therapy – therapies on the market,
encouraging clinical data and a long list of pharma collaborations.
Pricing and reimbursement takes a majority of the headlines but equally
important is producing these therapies in a scalable, cost-effective and
robust way, all the while developing a clear CMC and characterization
profile that satisfies the regulators. Cambridge Healthtech Institute’s Gene Therapy Manufacturing meeting takes a practical, case study
driven approach to the process development, scale-up and production of
gene therapies, tackling key topics such as AAV, lentivirus and
retrovirus process development and scale-up, CMO management from early
to late-stage development. http://www.bioprocessingsummit.com/gene-therapy-bioproduction/
genes
& vectors: Engineering Genes, Vectors, Constructs, and Clones
Exploring Strategies in Systems Engineering
and Synthetic Biology
JAN 20-21,
2020
San
Diego CA The demand for high-quality biotherapeutic proteins has never
been greater. Many variables still must be considered during the
engineering process, including verification and sequence analysis of the
gene or protein of interest, codon optimization, vector construction and
clone/host selection – a time-consuming and expensive process.
Additionally, protein expression scientists are now exploring new
engineering tools including synthetic biology and systems engineering.
Ultimately, these tools must be weighed against traditional expression
and production strategies to achieve the desired quantity and quality. https://www.chi-peptalk.com/genes-vectors-clones/
Good
Manufacturing Practice: Wikipedia http://en.wikipedia.org/wiki/Good_Manufacturing_Practice Broader
term: GxP
Host Cell Proteins Detection, Analysis and Control August 12-13,
2019 BOSTON MA A critical part of bioprocessing is the control of
process-related impurities such as host cell proteins (HCPs), which
co-purify with the drug substance and can cause adverse effects such as
immunogenicity. Analytical methods are available but coverage and
specificity is limited. Moreover, the emergence of new expression
systems, new products and new techniques such as mass spectrometry has
further compounded these limitations with regulators now pressing
companies for more HCP data. CHI’s Host Cell Proteins conference brings
together industry leaders to discuss critical HCP topics such as: risk
assessment and control strategies, HCP characterization, assay coverage,
critical reagents and platforming, plus questions relating to
biosimilars, in-process testing and the latest data supporting the link
between HCPs and immunogenicity.
http://www.bioprocessingsummit.com/Host-Cell-Proteins/
Industrial enzymes:
enzymes that are
commercially used in a variety of industries such as pharmaceuticals,
chemical production, biofuels, food &
beverage, and consumer products. Due to advancements in recent years, biocatalysis through
isolated enzymes is considered more economical than use of whole cells.
Enzymes may be used as a unit
operation within a process to generate a desired product, or may be
the product of interest. Industrial biological catalysis through enzymes
has experienced rapid growth in recent years due to their ability to
operate at mild conditions, and exceptional chiral and
positional specificity, things that traditional chemical processes lack.[1]
Wikipedia accessed 2019 Jan 21
https://en.wikipedia.org/wiki/Industrial_enzymes
Lyophilization and Emerging Drying Technologies
January 20-21, 2020 • San Diego, CA
the
latest trends and
challenges in lyophilization and emerging drying technologies. This
conference featured in-depth case studies, new and unpublished data and
discussions on developing scientifically sound freeze dried formulation,
process optimization for biologics and vaccines. It will also present
cutting edge research and case studies on freeze/thaw and formulation
challenges, drying in cartridges, storage stability, QbD and PAT
approaches and strategies for scale-up from R&D scale to full production
level, and selection of container closure systems.
https://www.chi-peptalk.com/lyophilization-drying-technologies
Lyophilization
includes spray drying, foam drying
Definitions,
Freezedryinginfo, Millrock Technologies http://www.freezedryinginfo.com/Definitions.html
about 30 terms
mammalian cell culture: Biological products produced
by recombinant
DNA (rDNA) technology in animal cell cultures include enzymes,
synthetic hormones,
immunobiologicals (monoclonal
antibodies, interleukins, lymphokines),
and anticancer
agents. Although many simpler proteins can be produced using rDNA in
bacterial cultures, more complex proteins that are glycosylated (carbohydrate-modified)
currently must be made in animal cells. …. The cost of growing mammalian
cell cultures is high, so research is underway to produce such complex
proteins in insect cells or in higher plants, use of single embryonic
cell and somatic embryos
as a source for direct gene transfer via particle bombardment, transit gene
expression and confocal
microscopy observation is one of its applications. Wikipedia
accessed 2018 Nov 18
https://en.wikipedia.org/wiki/Cell_culture#Concepts_in_mammalian_cell_culture
Narrower term: Chinese Hamster Ovary CHO cells
Method Development, Qualification & Validation
Developing Fit-for-Purpose Methods throughout the Product
Lifecycle
MARCH 4-5, 2019 Alexandria VA
From method development and qualification to
validation and transfer, it is a continuous yet interdependent process
from early R&D to QC and release; the objective is to prove that methods
selected are fit for their intended purpose. With an expanded portfolio
of newer formats and non-mAbs in the pipelines, knowledge, experience
and advanced techniques are critical to establish efficient, accurate
and fit-for-purpose analytical methods that can be subsequently
qualified, validated and transferred to release testing, thereby
improving efficiency and reducing cost, time and resources.
http://www.biotherapeuticsanalyticalsummit.com/Method-Development-Validation
Microbial Production January 17-18, 2019 • San Diego, CA
http://www.chi-peptalk.com/microbial-production-conference/
Microbial
expression systems offer significant advantages over other hosts by
providing faster development times, greater yields, lower production
costs, particularly in E. coli which
is one of the most widely used hosts for protein production. However,
limitations around glycosylation and central metabolic pathways poses
significant challenges… covered the latest developments in microbial
expression and production – from host strain development to metabolic
engineering, assembly to scale-up, downstream processing to potential
aggregation – with particular focus on the role of E.
coli for biotherapeutics, novel
products and other industrial applications.
microreactors:
Wikipedia
http://en.wikipedia.org/wiki/Microreactor
Alternately:
microbioreactors
molecular farming: The large scale production of pharmaceutically important and
commercially valuable RECOMBINANT
PROTEINS MeSH 2011
Oligonucleotide
CMC & Regulatory Boston March 26-28, 2019 Cambridge, MA
Program |
sessions
on new chemistries, novel delivery mechanisms and the most important
preclinical and clinical advances. Leading oligonucleotide scientists
deliver detailed case studies on antisense, RNA, aptamer and
oligonucleotide conjugates
PEGS:
the essential protein engineering summit
May 4-8,
2020 • Boston, MA Program | Conference
programs include protein and antibody engineering, cancer immunotherapy,
oncology, and emerging therapeutics.
PEGS
Europe 2019
Nov 18-22 Lisbon Portugal Conference programs include
Engineering, Oncology, Analytical, Immunotherapy, Expression and
Bispecifics.
PepTalk
January 20-24, 2020 • San Diego, CA Program |
Conference programs include Protein Engineering and Development,
Innovations in Discovery and Development, Antibody Therapeutics,
Formulation and Stability, Analytics & Impurities, Process Technologies
& Purification, Biotherapeutic expression & production, Alternative
expression & products.
pharming:
Use of transgenic animals to produce
drugs in their milk, urine or eggs. Transgenic plants can also be used.
(Tobacco is said to be particularly amenable to this application).
Process
Analytical Technology PAT:
The goal of PAT is to understand and control the manufacturing process, which is
consistent with our current drug quality system: quality cannot be tested
into products; it should be built-in or should be by design.
Process Analytical Technology is: a system for designing,
analyzing, and controlling manufacturing through timely measurements (i.e.,
during processing) of critical quality and performance attributes of raw and
in-process materials and processes with the goal of ensuring final product
quality. It is important to note that the term analytical in PAT is
viewed broadly to include chemical, physical, microbiological, mathematical, and
risk analysis conducted in an integrated manner.
OPS Process
Analytical Technology - (PAT) Initiative
FDA, CDER, Office of Medical Products & Tobacco
https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm088828.htm
Process Characterization and Control A best practices forum for the
translation of process understanding into control strategies for
maintaining quality throughout the product lifecycle August 15-16, 2019,
BOSTON MA
With the recent publication of process validation guidances from both US
and European regulators, the demonstration of process understanding,
identification of critical quality attributes and the implementation of
well-validated control strategies must now become a routine part of
biologics manufacturing operations. But significant ambiguities remain
in the specific steps that must be taken in the production of legacy and
new products, by companies of different scale and resources and for
specific product formats. http://www.bioprocessingsummit.com/Process-Characterization/
process
chemistry:
To compile a list of terms with their definitions
https://iupac.org/projects/project-details/?project_nr=2001-049-2-700
Glossary of terms used in
Process Chemistry/Manufacturing of Active Pharmaceutical Ingredients” and
“Pharmaceutics work in progress.
protein expression: Optimizing
Protein Expression
Enhancing Expression
Systems
APRIL 10-11, 2019 BOSTON MA
Expression
of heterologous proteins presents many challenges and understanding
expression systems is key. The 9th annual Optimizing
Protein Expression conference
delves into protein expression by examining and enhancing expression
systems, including CHO and other mammalian systems, E.
coli, yeast and baculovirus. What
is the best expression system for expressing your protein of choice?
Ease and cost of scale-up must be considered to ensure successful
bottom-line results. Experts will share case studies and disclose data
while divulging details of expression systems’ underlying mechanisms.
Comparing and contrasting systems will also be featured to increase
understanding in the quest for greater productivity.
Program | .See also Expression gene & protein
protein
expression difficult:
Difficult-to-Express Proteins Overcoming Expression Challenges
APRIL 8-9, 2019 Boston MA
Proteins are each unique and bring unique challenges when attempting to tame
them into submission. This conference examines the challenges researchers
encounter when striving for high-yield production of “difficult-to-express”
proteins (DTEPs) and the strategies and technologies that have proven successful
in overcoming those challenges. Some of the difficulties encountered include
solubility, proper folding, inability to crystallize and aggregation and
formation of inclusion bodies. Researchers employ a range of problem-specific
solutions to achieve expression including genetic modifications, manipulating
how a target protein is produced and employing protein tags. In addition, the
identification of DNA coding sequences along with the use of high-throughput
approaches has brought about significant improvements. Program
protein
process management: The demand for
protein-based therapeutics grows by 50% each year, yet the time-consuming and
often unpredictable nature of working with peptide and protein-based
therapeutics is hampered by the tremendous cost of developing a product—up to
$3 billion.
Protein Purification and Recovery January 21-22 , 2020 • San Diego, CA | In
the world of biologics, purifying protein remains a constant bottleneck
and nagging headache. A process that works great for one protein, may
not work at all for the next. Not only are the tasks challenging, but
outcomes must be ensured to result in properly folded protein. CHI’s
Protein Purification and Recovery conference examines the strategies
that efficiently lead to pure protein for research or therapeutic use.
This leading conference illustrates how ‘traditional’ strategies
(protein A, chromatography, affinity tags) are being innovated and
improved, while also demonstrating the new technologies that are being
introduced and integrated to help streamline purification while ensuring
quality. This conference will also explore the finesse required when
purifying complex molecules, such as membrane proteins, bispecifics and
antibody-drug conjugates, in the ever-present quest for purity.
https://www.chi-peptalk.com/protein-purification
Recombinant
Protein Expression and Production January
21-22, 2020 • San Diego, CA
Program | Biopharmaceuticals
currently represent the fastest-growing sector of the pharmaceutical
industry, driven by a rapid expansion in the manufacture of recombinant
protein-based drugs. Great
strides have been made in the expression, production, and purification
of biotherapeutics. However, hurdles remain. The efficient expression
and production of these valuable biomolecules face challenges in
improving their quantity and quality while minimizing time and cost.
Thus, higher-throughput expression and purification as well as more
flexible expression platforms are in even greater demand. Unfortunately,
there is no “universal” production system which can guarantee high
yields of recombinant protein, particularly as every biomolecule itself
causes its own issues in terms of expression.
https://www.chi-peptalk.com/protein-expression-production
tissue culture: See cell culture.
IUPAC Biotech
transient protein production: Optimizing
Expression Platforms Tools for Effective Expression, Production, and
Purification JANUARY 21-22, 2020
San Diego CA
The utilization of engineered therapeutic proteins for basic research,
clinical diagnostics, and therapy continues to expand. Consequently,
protein expression laboratory managers and researchers face challenges
for efficient expression, production, and purification even while
improving quantity and quality and minimizing time and cost.
Transient protein production (TPP)
has the advantage of speed and limiting risk while stable transfection –
the longer and more complex process – has the advantage of producing
long-term expression of the biotherapeutic of interest. The rapidly
increasing need for recombinant proteins necessitates further
improvements in both technologies. https://www.chi-peptalk.com/optimizing-expression-platforms
upstream processing: the entire process from early cell
isolation and cultivation, to cell banking and culture expansion of the
cells until final harvest (termination of the culture and collection of
the live cell batch)....The upstream part of a bioprocess refers to the
first step in which microbes/cells are grown, e.g. bacterial or
mammalian cell lines (see cell
culture),
in bioreactors.
Upstream processing involves all the steps related to inoculum
development, media development, improvement of inoculum by genetic
engineering process, optimization of growth kinetics so that product
development can improve tremendously. Fermentation has two parts:
upstream and downstream. After product development, the next step is the
purification of product for desired quality. When they reach the desired
density (for batch and fed-batch cultures) they are harvested and moved
to the downstream section of the bioprocess.
Wikipedia bioprocessing accessed 2018
Aug 17
https://en.wikipedia.org/wiki/Bioprocess
See related downstream processing Upstream
processing stream Bioprocessing Summit Aug
12-,16, 2019 Boston MA
The Upstream Processing stream details best practices for the
foundations of protein expression that support biological drugs,
including cell line development, culturing cells, and issues surrounding
bioproduction, such as integrating disposable systems, bioreactor
engineering, and developing small-scale models for scaling up
production. Synthetic biology, genetic engineering, predictive and
information technologies, and next-gen strategies will be explored as
part of the ongoing efforts to ensure quality while achieving
manufacturability and reaching bioprocess goals.https://www.bioprocessingsummit.com/stream/upstream-processing/
vector: Cell technologies
Bioprocessing Resources
Bioprocessing Conferences
http://www.healthtech.com/conferences/upcoming.aspx?s=BPS
Bioprocessing Summit
http://www.bioprocessingsummit.com/
PepTalk The Protein Science Week http://www.chi-peptalk.com/
Protein Engineering Summit PEGS http://www.pegsummit.com/
Bioprocessing Short courses http://www.healthtech.com/Conferences_Upcoming_ShortCourses.aspx?s=BPS
Glossary of
Pharmaceutical and Biopharmaceutical Terms, revised annually 500 plus terms http://www.contractpharma.com/glossary
Definitions,
Freezedryinginfo, Millrock Technologies http://www.freezedryinginfo.com/Definitions.html
about 30 terms
ISPE International Society Pharmaceutical
Engineering ISPE Glossary of Pharmaceutical and Biotechnology Terminology http://www.ispe.org/glossary
Manufacturing and regulatory
IUPAC International Union of Pure and Applied Chemistry, Glossary for
Chemists of terms used in biotechnology. Recommendations, Pure & Applied
Chemistry 64 (1): 143-168, 1992. 200 + definitions.
IUPAC International Union of Pure and Applied Chemistry, Compendium of
Chemical Terminology: Recommendations, compiled by Alan D. McNaught and
Andrew Wilkinson, Blackwell Science, 1997. "Gold Book" 6500+
definitions. http://goldbook.iupac.org/
IUPAC International Union of Pure and Applied Chemistry, GLOSSARY FOR CHEMISTS
OF TERMS USED IN TOXICOLOGY Clinical Chemistry Division, Commission on
Toxicology, Pure and Appl. Chem., 65 ( 9): 2003- 2122, 1993. 1200+
definitions. http://www.iupac.org/reports/1993/6509duffus
IUPAC, Glossary of
terms related to pharmaceutics, Pure and Applied Chemistry 81, 971–999,
2009, 168 definitions http://www.iupac.org/publications/pac/pdf/2009/pdf/8105x0971.pdf
How
to look for other unfamiliar terms
|
|